Renalytix (RNLX) Competitors $0.21 +0.01 (+5.66%) (As of 10/7/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends RNLX vs. MGRX, ENZ, XGN, CCM, BNR, ATIP, TOI, PMD, MRAI, and BRTXShould you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Mangoceuticals (MGRX), Enzo Biochem (ENZ), Exagen (XGN), Concord Medical Services (CCM), Burning Rock Biotech (BNR), ATI Physical Therapy (ATIP), Oncology Institute (TOI), Psychemedics (PMD), Marpai (MRAI), and BioRestorative Therapies (BRTX). These companies are all part of the "healthcare" industry. Renalytix vs. Mangoceuticals Enzo Biochem Exagen Concord Medical Services Burning Rock Biotech ATI Physical Therapy Oncology Institute Psychemedics Marpai BioRestorative Therapies Mangoceuticals (NASDAQ:MGRX) and Renalytix (NASDAQ:RNLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the MarketBeat Community prefer MGRX or RNLX? Renalytix received 9 more outperform votes than Mangoceuticals when rated by MarketBeat users. CompanyUnderperformOutperformMangoceuticalsN/AN/ARenalytixOutperform Votes934.62% Underperform Votes1765.38% Does the media favor MGRX or RNLX? In the previous week, Mangoceuticals had 17 more articles in the media than Renalytix. MarketBeat recorded 17 mentions for Mangoceuticals and 0 mentions for Renalytix. Mangoceuticals' average media sentiment score of 0.06 beat Renalytix's score of 0.00 indicating that Mangoceuticals is being referred to more favorably in the media. Company Overall Sentiment Mangoceuticals Neutral Renalytix Neutral Do insiders and institutionals hold more shares of MGRX or RNLX? 56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 9.9% of Renalytix shares are held by institutional investors. 39.3% of Mangoceuticals shares are held by insiders. Comparatively, 18.3% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend MGRX or RNLX? Renalytix has a consensus price target of $3.00, suggesting a potential upside of 1,348.58%. Given Renalytix's higher possible upside, analysts clearly believe Renalytix is more favorable than Mangoceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ARenalytix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, MGRX or RNLX? Mangoceuticals has higher earnings, but lower revenue than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMangoceuticals$730K6.16-$9.21M-$6.45-0.35Renalytix$2.29M7.50-$33.46M-$0.39-0.53 Which has more risk & volatility, MGRX or RNLX? Mangoceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500. Is MGRX or RNLX more profitable? Mangoceuticals has a net margin of -1,053.93% compared to Renalytix's net margin of -1,461.60%. Renalytix's return on equity of 0.00% beat Mangoceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mangoceuticals-1,053.93% -243.34% -200.73% Renalytix -1,461.60%N/A -281.40% SummaryMangoceuticals and Renalytix tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Renalytix News Delivered to You Automatically Sign up to receive the latest news and ratings for RNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNLX vs. The Competition Export to ExcelMetricRenalytixMedical laboratories IndustryComputer SectorNASDAQ ExchangeMarket Cap$17.18M$2.57B$24.01B$8.53BDividend YieldN/A1.69%2.75%4.14%P/E Ratio-0.5328.98252.9815.12Price / Sales7.50190.963,721.9993.03Price / CashN/A507.8332.1034.05Price / Book-2.074.416.995.02Net Income-$33.46M-$31.39M$670.43M$225.46M7 Day PerformanceN/A1.46%-0.33%0.37%1 Month Performance8.37%-1.36%0.64%3.57%1 Year Performance-80.28%35.71%20.32%29.42% Renalytix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNLXRenalytix1.2397 of 5 stars$0.21+5.7%$3.00+1,348.6%-79.7%$17.18M$2.29M-0.53100Gap UpMGRXMangoceuticals1.4168 of 5 stars$2.42-0.4%N/A-98.5%$60.06M$866,792.00-0.383News CoverageENZEnzo Biochem0.5822 of 5 stars$1.15+1.8%N/A-15.7%$59.18M$33.34M0.00520Dividend AnnouncementAnalyst ForecastNews CoverageHigh Trading VolumeXGNExagen4.1971 of 5 stars$2.59-0.8%$7.00+170.3%+48.6%$45.03M$56.66M-2.67220Negative NewsCCMConcord Medical Services1.6687 of 5 stars$7.95+7.0%N/AN/A$34.50M$471.70M0.00970Analyst ForecastShort Interest ↓News CoverageGap DownBNRBurning Rock Biotech0.7289 of 5 stars$2.77-0.7%N/A-70.3%$28.38M$509.81M-0.581,390Gap DownATIPATI Physical Therapy1.6517 of 5 stars$5.98+2.2%N/A-19.3%$26.29M$729.33M-0.445,600Upcoming EarningsShort Interest ↓News CoverageHigh Trading VolumeTOIOncology Institute2.3103 of 5 stars$0.31-2.5%$2.50+701.3%-85.7%$23.23M$361.07M-0.39660Gap DownPMDPsychemedicsN/A$2.32flatN/A-6.5%$13.47M$20.79M-2.97140Positive NewsMRAIMarpaiN/A$0.93+14.8%$6.00+545.2%+76.9%$12.78M$37.15M-0.28150BRTXBioRestorative Therapies4.0457 of 5 stars$1.54+0.8%$18.00+1,067.5%-12.2%$10.67M$174,100.00-0.767Short Interest ↓Positive News Related Companies and Tools Related Companies MGRX Competitors ENZ Competitors XGN Competitors CCM Competitors BNR Competitors ATIP Competitors TOI Competitors PMD Competitors MRAI Competitors BRTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNLX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
